Respironics
This article was originally published in The Gray Sheet
Executive Summary
Board of directors elects Executive VP and Chief Operating Officer Dennis Meteny to succeed Gerald McGinnis as president and CEO. Company founder McGinnis becomes chairman of the board, replacing George Magovern, who continues as a director. The changes were made because Magovern and McGinnis prefer "more specialized roles in the company's operations," Respironics says. The company also appoints Daniel Bevevino as controller and chief financial officer
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.